Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 23, 2011

Primary Completion Date

September 13, 2012

Study Completion Date

September 13, 2012

Conditions
Ependymoma
Interventions
DRUG

Erlotinib

continuous oral Erlotinib 85 mg/m\^2 per day

Trial Locations (21)

15224

Childrens Hospital of Pittsburgh of UPMC, Pittsburgh

20010

Children's National Medical Center -D.C. Center for Cancer and Blood Disorders, Washington D.C.

30322

Emory University Children's Healthcare of Atlanta, Atlanta

33136

University of Miami, Miami

35233

University of Alabama at Birmingham, Birmingham

55455

University of Minnesota - Amplatz Children's Hospital, Minneapolis

80045

The Children's Hospital Center for Cancer and Blood Disorders, Aurora

92868

Children's Hospital of Orange County (CHOC), Orange

94304

Packard Children's Hospital, Palo Alto

97124

Oregon Health & Sciences University Doernbecher Children's Hospital, Portland

53705-2275

University of Wisconsin, Madison

T6G 2B7

Stollery Children's Hospital, Edmonton

V6H 3V4

Children's and Women's Health Center of BC, Vancouver

M5G 1X8

Hospital for Sick Children, Toronto

B4 6NH

Birmingham Children's Hospital Oncology Department, Birmingham

G3 8SJ

Royal Hospital for Sick Children, Glasgow

LS1 3EX

Paediatric Oncology and Haematology Offices,, Leeds

L12 1AP

Alder Hey Children's NHS Foundation Trust, Liverpool

M13 9W2

Royal Manchester Children's Hospital Ward 84, Manchester

NG7 2UH

University of Nottingham, Nottingham

SM2 5pt

Royal Marsden Hospital, Sutton

Sponsors
All Listed Sponsors
lead

OSI Pharmaceuticals

INDUSTRY

NCT01247922 - Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 | Biotech Hunter | Biotech Hunter